Pharmacokinetic modeling of a novel hypoxia PET tracer [<sup>18</sup>F]HX4 in patients with non-small cell lung cancer.

Pharmacokinetic modeling of a novel hypoxia PET tracer [¹⁸F]HX4 in patients with non-small cell lung cancer.

Verwer, E E; Zegers, C M L; van Elmpt, W; Wierts, R; Windhorst, A D; Mottaghy, F M; Lambin, P; Boellaard, R.

Afiliación

Verwer EE; Department of Radiology & Nuclear Medicine, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Zegers CM; Department of Nuclear Medicine & Molecular Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
van Elmpt W; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Wierts R; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Windhorst AD; Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Mottaghy FM; Department of Radiology & Nuclear Medicine, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Lambin P; Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Boellaard R; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.

EJNMMI Phys ; 3(1): 30, 2016 Dec.

Article en En | MEDLINE | ID: mdl-27957730

Palabras clave

18F-3-Fluoro-2-(4-((2-Nitro-1H-Imidazol-1-yl)Methyl)-1H-1,2,3-Triazol-1-yl)Propan-1-ol ([18F]HX4); Hypoxia; Image-derived input function (IDIF); Molecular imaging; Non-small cell lung cancer (NSCLC); Positron emission tomography (PET); Standardized uptake value (SUV); Tracer kinetic modeling; Tumor-to-blood ratio